Market
Scenario:
Black lung disease or coal workers' pneumoconiosis is caused
by long exposure to coal dust and is commonly diagnosed in many of the coal
miners. The medical condition is characterized by a progressive building of the
inhaled coal dust in the lungs, which may lead to inflammation, fibrosis,
necrosis, and others. Increasing prevalence of black lung disease is one of the
major drivers of market growth during the forecast period. According to the
2005-2016 report of the Health and Safety Executive, it was estimated that the
average number of new cases for black lung disease was 25 (on a yearly basis).
Moreover, increasing mining activities, increasing research and development
expenses, and rising healthcare expenditures boost the market growth. In 2015,
according to the Office for National Statistics, the total healthcare
expenditure was estimated to about USD 271 billion within U.K.
However, factors such as lack of awareness, limited
availability of medicinal treatment options followed by the high cost of surgical
therapeutics including lung transplantation and stem cell therapy are estimated
to restrain the market growth during the forecast period. In 2016, the average
cost of lung transplantation was expected to be around USD 111, 618.
Get
Exclusive Sample Report @
https://www.marketresearchfuture.com/sample_request/5711
Segmentation:
The global black lung disease market is segmented by the
type, diagnosis, treatment, and end-user.
On the basis of the type, the market is segmented into simple
coal worker’s pneumoconiosis, complicated coal worker’s pneumoconiosis, and
others. On the basis of the diagnosis, the market is segmented into biopsy,
imaging, full blood count, pulmonary/lung function tests, physical examination,
and others. The imaging segment is segmented into CT, X-ray, and others. On the
basis of the treatment, the market is segmented into oxygen therapy,
bronchodilators, lung transplant, stem cell therapy, and others. On the basis
of the end users, the market is segmented into hospitals & clinics,
research organizations & academic institutes, diagnostic centers &
labs, and others.
Intended
Audience:
·
Pharmaceutical Companies
·
Biotechnological Institutes
·
Government and Private Laboratories
·
Research and Development (R&D) Companies
·
Medical Research Laboratories
·
Market Research and Consulting Service Providers
Regional
Analysis:
The Americas dominate the global black lung disease market
owing to a well-developed healthcare sector and huge patient population.
Moreover, increasing healthcare expenditure and presence of the key players
like GENERAL ELECTRIC and Medtronic within the regions boosts the growth of the
market in the Americas. Additionally, developed economies of the region like
U.S. and Canada boost.
Europe is the second largest market for black lung disease
and is followed by Asia Pacific. Rising government support, huge patient population,
and rising healthcare expenditure are some of the major drivers for market
growth within the region. On a regional basis, the European black lung disease
market is segmented into Western Europe and Eastern Europe. Western Europe is
estimated to lead the regional market due to the presence of developed
economies like Germany, U.K, France, and others within the region.
Asia Pacific is the fastest growing region for the black lung
disease market. Factors such as the presence of a huge patient population,
continuously developing healthcare sector, and rising healthcare expenditure
drives the market growth within the region. In 2017, a study published in the
International Journal of Environmental Research and Public Health journal
stated that the number of new cases for pneumoconiosis was about 26,873 in
2014, of which about 13,846 (51.52%) accounted for black lung disease.
The Middle East & Africa has the least share in the
global black lung disease market. Presence of poor economies, lack of a developed
healthcare sector, stringent government policies, and lack of awareness of the
disease, restrain the market growth, especially within the Africa region. A
majority of the market of this region is held by the Middle East.
Key players
in global black lung disease:
The key players for the global black lung disease market are
Boehringer Ingelheim International GmbH (Germany), GlaxoSmithKline plc (U.K),
Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), AstraZeneca
(U.K), Koninklijke Philips N.V. (The Netherlands), GENERAL ELECTRIC (U.S.),
Siemens AG (Germany), TOSHIBA CORPORATION (Japan), Medtronic (U.S.), and
others.
Get Your
Customized Report @ https://www.marketresearchfuture.com/reports/black-lung-disease-market-5711
TABLE OF
CONTENT:
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
TOC
Continued…!
Get
Discount @
About
US:
Market Research Future (MRFR), enable customers to
unravel the complexity of various industries through Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R),
Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact
Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone:
+1
646 845 9312
No comments:
Post a Comment